Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.

Platelet-activating factor (PAF) is a bioactive phospholipid (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) synthesized by a variety of mammalian cell types. PAF induces hypotension, and activates neutrophils and platelets, among other actions. Removal of the acetyl moiety abolishes biological activity, so this reaction may regulate the concentration of PAF and its physiological effects. We have studied the significance of this reaction, which is catalyzed in vitro by an acetylhydrolase present in mammalian plasma, blood cells, and tissues. We have shown that the plasma PAF-acetylhydrolase is responsible for the degradation of PAF in whole human blood and that alternate pathways for PAF degradation in plasma or blood cells are negligible. Human plasma PAF-acetylhydrolase is associated with low and high density lipoproteins (LDL and HDL with apoE). We have confirmed that the activity is a stable component of these particles by density gradient ultracentrifugation, chromatography on heparin-agarose, and immunoprecipitation. The LDL-associated activity accounts for most or all of the PAF degradation that occurs in plasma ex vivo, while the HDL-associated activity contributes little to this process. However, the two activities likely are due to a single protein since the HDL- and LDL-associated PAF-acetylhydrolase activities can transfer from one lipoprotein to the other. These transfer processes are pH-dependent and specific, since they only occur from LDL to a well characterized subclass of HDL (apoE-containing HDL) and vice versa. We discuss the equilibrium between the two particles and the role that this process may have in vivo.

• Publication year

  1987

• Venue

  Journal of Biological Chemistry

• Publication date

  1987-03-25

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/s0021-9258(18)61335-3PMID 3549727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human plasma platelet-activating factor acetylhydrolase. Purification and properties.

  1987cited by this paper
• Dietary fish oils reduce plasma levels of platelet activating factor precursor (lyso-PAF) in rats.

  1986cited by this paper
• Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells.

  1986cited by this paper
• Substrate specificity and partial characterization of the PAF-acylhydrolase in human serum that rapidly inactivates platelet-activating factor.

  1986cited by this paper
• Platelet-activating factor-mediated vasoconstriction and glycogenolysis in the perfused rat liver.

  1986cited by this paper
• Platelet activating factor: a biologically active phosphoglyceride.

  1986cited by this paper
• The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease).

  1985cited by this paper
• Demonstration of functional low-density lipoprotein receptors by protein blotting in fibroblasts from a subject with homozygous receptor-negative familial hypercholesterolemia.

  1985cited by this paper
• Substrate specificity of plasma lysolecithin acyltransferase and the molecular species of lecithin formed by the reaction.

  1985cited by this paper
• Acylation of lysophospholipids by rabbit alveolar macrophages. Specificities of CoA-dependent and CoA-independent reactions.

  1985cited by this paper
• Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate.

  1985cited by this paper
• Association of platelet-activating factor with primary acquired cold urticaria.

  1985cited by this paper
• 1-O-alkyl-2-acyl-sn-glycero-3-phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl-glycerophosphorylcholine cycle.

  1985cited by this paper
• CoA-independent transfer of arachidonic acid from 1,2-diacyl-sn-glycero-3-phosphocholine to 1-O-alkyl-sn-glycero-3-phosphocholine (lyso platelet-activating factor) by macrophage microsomes.

  1985cited by this paper
• Chemical and biochemical aspects of platelet activating factor: A novel class of acetylated ether‐linked choline‐phospholipids

  1985cited by this paper
• Inactivation of platelet activating factor by rabbit platelets. Lyso-platelet activating factor as a key intermediate with phosphatidylcholine as the source of arachidonic acid in its conversion to a tetraenoic acylated product.

  1985cited by this paper
• Effects of acetyl glyceryl ether of phosphorylcholine (platelet activating factor) on ventricular preload, afterload, and contractility in dogs.

  1984cited by this paper
• Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets.

  1984cited by this paper
• Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin.

  1984cited by this paper
• Presence of platelet-activating factor in blood from humans and experimental animals. Its absence in anephric individuals.

  1984cited by this paper
• Plasma lipoproteins: apolipoprotein structure and function.

  1984cited by this paper
• Metabolism of platelet-activating factor in human platelets. Transacylase-mediated synthesis of 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine.

  1984cited by this paper
• Human serum acid-labile factor is an acylhydrolase that inactivates platelet-activating factor.

  1983cited by this paper
• Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats.

  1983cited by this paper
• Lipoprotein receptors and cholesterol homeostasis.

  1983cited by this paper
• Metabolic fate of platelet-activating factor in neutrophils.

  1983cited by this paper
• Biosynthesis of platelet activating factor in rabbit polymorphonuclear neutrophils.

  1983cited by this paper
• Metabolism of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by cell cultures.

  1982cited by this paper
• Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF).

  1982cited by this paper
• A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid).

  1981cited by this paper
• In vivo metabolism of a new class of biologically active phospholipids: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a platelet activating-hypotensive phospholipid.

  1981cited by this paper
• 1-O-Alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants.

  1981cited by this paper
• Subfractionation of human high density lipoproteins by heparin-Sepharose affinity chromatography.

  1980cited by this paper
• Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF).

  1980cited by this paper
• Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor.

  1980cited by this paper
• LEUKOCYTE-DEPENDENT HISTAMINE RELEASE FROM RABBIT PLATELETS

  1972cited by this paper
• The distribution and composition of serum lipoproteins in eighteen animals.

  1971cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• A rapid method of total lipid extraction and purification.

  1959cited by this paper

• Correlation between lipoprotein-associated phospholipase A2 and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus: A cross-sectional study.

  2025cites this paper
• A Complex of Type I Platelet-Activating Factor Acetylhydrolase (PAF-AH) Catalytic Subunits Switches from α1/α2 Heterodimer to α2/α2 Homodimer during Adipocyte Differentiation of 3T3-L1 Cells.

  2023cites this paper
• Research Advance of Chinese Medicine in Treating Atherosclerosis: Focus on Lipoprotein-Associated Phospholipase A2

  2023cites this paper
• Associations between healthy food groups and platelet-activating factor, lipoprotein-associated phospholipase A2 and C-reactive protein: a cross-sectional study

  2023cites this paper
• Lipoprotein-associated phospholipase A2: A paradigm for allosteric regulation by membranes

  2022cites this paper
• The impact of type 2 immunity and allergic diseases in atherosclerosis

  2022cites this paper
• Macroalgal Proteins: A Review

  2022cites this paper
• Platelet Activating Factor (PAF): A Mediator of Inflammation

  2022cites this paper
• Cathepsin G-induced malignant progression of MCF-7 cells involves suppression of PAF signaling through induced expression of PAFAH1B2.

  2022cites this paper
• A negative association between low-density lipoprotein cholesterol level and infection risk in elderly stage 5 chronic kidney disease patients

  2021cites this paper
• Phospholipase Signaling in Breast Cancer.

  2021cites this paper
• Switching the substrate specificity of lysoplasmalogen‐specific phospholipase D

  2021cites this paper
• Current Understanding of the Immunomodulatory Activities of High-Density Lipoproteins

  2021cites this paper
• The lipid biology of sepsis

  2021cites this paper
• Prolyl endopeptidase-like is a (thio)esterase involved in mitochondrial respiratory chain function

  2021cites this paper
• Molecular pathways linking oxylipins to nociception in rats.

  2020cites this paper
• High-Density Lipoprotein (HDL) in Allergy and Skin Diseases: Focus on Immunomodulating Functions

  2020cites this paper
• Effect of acyl and alkyl analogs of platelet-activating factor on inflammatory signaling.

  2020cites this paper
• Influence of lipoprotein-associated phospholipase A2 mass on prognosis value of baseline platelet count for clinical outcomes after acute ischemic stroke.

  2020cites this paper
• Clinical significance of plasma PAF acetylhydrolase activity measurements as a biomarker of anaphylaxis: Cross-sectional study

  2020cites this paper
• Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting.

  2020cites this paper
• Interface of Phospholipase Activity, Immune Cell Function, and Atherosclerosis

  2020influential citation
• Lipoprotein‐associated phospholipase A2: The story continues

  2019cites this paper
• High-density lipoprotein: Quality versus quantity in type 2 diabetes mellitus

  2019cites this paper
• Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives

  2019cites this paper
• Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein-Associated Phospholipase A2 Activity: A Cross-Sectional Study.

  2019cites this paper
• Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF

  2018cites this paper
• Novel enzymatic method for assaying Lp-PLA2 in serum.

  2018cites this paper
• Measurement of Lipoprotein-Associated Phospholipase A2 by Use of 3 Different Methods: Exploration of Discordance between ELISA and Activity Assays.

  2018cites this paper
• Pharmacological Intervention to Modulate HDL: What Do We Target?

  2018cites this paper
• Inflammatory Mediators in Ovarian Follicles: The Possible Role of Platelet-Activating Factor and its Metabolic Enzyme

  2017cites this paper
• Chapter 5 Lipoprotein-Associated Phospholipase A 2 – Pathophysiological Role and Clinical Significance as a Cardiovascular Biomarker

  2017cites this paper
• ACETYLHYDROLASE AS BOMARKER FOR ANAPHYLAXIS

  2017cites this paper
• Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies

  2017cites this paper
• Shark derivatives (Alkylglycerols, Squalene, Cartilage) as putative nutraceuticals in oncology

  2017cites this paper
• Modulation of Receptor Signaling and Functional Selectivity in Neutrophils

  2017cites this paper
• Risk Factors Associated with Coronary Artery Disease in Gaza

  2017cites this paper
• HDL-A molecule with a multi-faceted role in coronary artery disease.

  2016cites this paper
• Lipases and their inhibitors in health and disease.

  2016cites this paper
• CLOPIDOGREL BINDS TO Lp-PLA2 AND INHIBITS THE ENZYME ACTIVITY. A NEW PLEIOTROPIC EFFECT OF THIS ANTIPLATELET DRUG?

  2016cites this paper
• Lipoprotein-associated phospholipase A2 distribution among lipoproteins differs in type 1 diabetes.

  2016cites this paper
• Radiation therapy generates platelet-activating factor agonists

  2016cites this paper
• Hypertrophic Mesenteric Adipose Tissue May Play a Role in Atherogenesis in Inflammatory Bowel Diseases

  2016cites this paper
• Childhood Basal Ganglia Stroke and its Association with Trivial Head Trauma

  2016cites this paper
• Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2).

  2016cites this paper
• Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution

  2016cites this paper
• Plasma PAF-AH (PLA2G7): Biochemical Properties, Association with LDLs and HDLs, and Regulation of Expression.

  2015cites this paper
• Lipoprotein-Associated Phospholipase A2 – Pathophysiological Role and Clinical Significance as a Cardiovascular Biomarker

  2015cites this paper
• The role of LDL-bound apoJ in the development of atherosclerosis

  2015cites this paper
• Risk multipliers for severe food anaphylaxis

  2015cites this paper
• Platelet-Activating Factor (PAF) in Infectious Diseases

  2015cites this paper
• Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.

  2015cites this paper
• Overview of PAF-Degrading Enzymes.

  2015cites this paper
• Intracellular PAF-Acetylhydrolase Type I.

  2015cites this paper
• Naturally Occurring Missense Mutation in Plasma PAF-AH Among the Japanese Population.

  2015cites this paper
• Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.

  2015cites this paper
• incorporating biomarkers into clinical trials in cardiovascular medicine

  2014cites this paper
• Protective role of Lipoprotein-Associated Phospholipase A2 Gene (A379V) Polymorphism against Myocardial Infarction among Egyptians

  2014cites this paper
• Therapeutics , Targets , and Chemical Biology Chemotherapeutic Agents Subvert Tumor Immunity by Generating Agonists of Platelet-Activating Factor

  2014cites this paper
• Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor.

  2014cites this paper
• Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) bound to LDL and HDL.

  2014cites this paper
• To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase

  2014cites this paper
• Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy

  2014cites this paper
• Pathophysiological Aspects of Lipoprotein-Associated Phospholipase A 2 : A Brief Overview

  2014cites this paper
• Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B

  2014cites this paper
• Incorporating biomarkers into clinical trials in cardiovascular medicine

  2014cites this paper
• Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases.

  2014cites this paper
• Lipoprotein associated phospholipase A2 enzyme; possible new roles and inhibition for therapeutic intervention -

  2014cites this paper
• Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials

  2014cites this paper
• Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond1

  2013cites this paper
• [Clinical role of lipoprotein-associated phospholipase A2].

  2013cites this paper
• Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.

  2013cites this paper
• Clinical Research Lipoprotein-Associated Phospholipase A 2 (Lp-PLA 2 ) in Acute Coronary Syndrome: Relationship With Low-Density Lipoprotein Cholesterol

  2013cites this paper
• Determination of phospholipase activity of PAF acetylhydrolase.

  2013cites this paper
• Role of Lipoproteins in Carotid Arterial Disease

  2013cites this paper
• Methods in Free Radical Biology and Medicine Determination of phospholipase activity of PAF acetylhydrolase

  2013cites this paper
• Structural basis of specific interactions of Lp-PLA2 with HDL revealed by hydrogen deuterium exchange mass spectrometry[S]

  2013cites this paper
• Proteomics investigations of HDL: challenges and promise.

  2012cites this paper
• Structural basis of specific interactions of Lp-PLA2 with HDL revealed by deuterium exchange mass spectrometry.

  2012cites this paper
• Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases Modulation of oxidative stress, infl ammation, and atherosclerosis by lipoprotein-associated phospholipase A 2

  2012cites this paper
• Platelet‐activating factor detection, metabolism, and inhibitors in the ethanologenic bacterium Zymomonas mobilis

  2012cites this paper
• Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker

  2012cites this paper
• Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up.

  2012cites this paper
• Lipoprotein-Associated Phospholipase A2 Activity Predicts Cardiovascular Events in High Risk Coronary Artery Disease Patients

  2012cites this paper
• Proteomics of inflammatory and oxidative stress response in cows with subclinical and clinical mastitis.

  2012cites this paper
• Effects of HAART on Platelet-Activating Factor Metabolism in Naive HIV-Infected Patients I: Study of the Tenofovir-DF/Emtricitabine/Efavirenz HAART Regimen

  2012cites this paper
• PURIFICATION AND CHARACTERIZATION OF BLOOD ASPIRIN HYDROLASES

  2012cites this paper
• Lipoprotein-Associated Phospholipase A 2 Bound on High-Density Lipoprotein Is Associated With Lower Risk for Cardiac Death in Stable Coronary Artery Disease Patients

  2012cites this paper
• Plasma platelet-activating factor-acetyl hydrolase activity and the levels of free forms of biomarker of lipid peroxidation in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage.

  2012cites this paper
• Outils diagnostique et thérapeutique innovants de la dysfonction vasculaire au cours des maladies artérielles périphériques.

  2012influential citation
• Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2

  2012influential citation
• In Vivo Effects of a Ginkgo Biloba Extract on Platelet Activating Factor Metabolism in Two Asymptomatic Hiv-Infected Patients

  2011cites this paper
• The metabolic serine hydrolases and their functions in mammalian physiology and disease.

  2011cites this paper
• Serum platelet-activating factor acetylhydrolase activity: relationship with metabolic syndrome in women with history of gestational diabetes mellitus

  2011cites this paper
• Membrane lipid composition differentially modulates the function of human plasma platelet activating factor-acetylhydrolase.

  2011cites this paper
• and cell-mediated oxidation PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper-

  2011cites this paper
• Lipoprotein-associated phospholipase A(2) interacts with phospholipid vesicles via a surface-disposed hydrophobic α-helix.

  2011cites this paper
• Composition lipidique et oxydation des lipoprot eines de basse densit e (LDL) plasmatiques en relation avec l'activation des plaquettes sanguines.

  2011cites this paper
• Lp‐PLA2– a novel risk factor for high‐risk coronary and carotid artery disease

  2011cites this paper
• Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).

  2011cites this paper